leisure time -WSS

leisure time

author：hotspot 2025-09-30 00:50:06 - browse：9753

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Is it ever OK for doctors to lie to their patients?

WSS

New air purifier tech could be key to improving indoor air quality

Warren pushes Witty on UnitedHealth's control over physicians

As demand for Covid shots wanes, Moderna seeks its next success

Guidelines to prevent youth baseball injuries need more muscle

Medical leaders decry Supreme Court decision on affirmative action

Welsh Carson private equity firm escapes from FTC antitrust case

entertainment

leisure time

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Brain technologies pose threats that are all too real, experts warn

23andMe had bad news about my health. I wish a person had delivered it

As health system earnings go up, health insurance stocks go down

Virginia high school admissions case could be legal follow

The creative science of coining drug names

Hepatitis C has a cure — but many Americans still lack access to it

Wildfire smoke exposes gaps in outdoor worker protections

Hepatitis C has a cure — but many Americans still lack access to it

The creative science of coining drug names

focus

Novavax promises a turnaround & Lilly roils the obesity market

AI for drug discovery: Experts on separating hype from reality

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

PBM executives asked to testify by House panel

AltruBio raises $225 million to develop ulcerative colitis drug

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

focus

leisure time

knowledge

focus